FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment; It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated. The FDA also gave approval to entrectinib for the treatment of adults with metastatic non–small cell lung cancer whose tumors are ROS1 positive.
FDA has granted accelerated approval to Genentech’s entrectinib, sold as Rozlytrek, for the treatment of adult and adolescent patients with solid tumors with that have the neurotrophic tyrosine receptor kinase (NTRK) gene fusion and for whom there are no effective treatments.
The approval of the tissue agnostic therapy represents a new paradigm in cancer treatment where cancers are treated based on a common biomarker seen across different tumors rather than based on the location in the body where the tumor originated. Last year, the FDA approved larotrectinib (Vitrakvi) for the treatment of adult and pediatric patients with advanced solid tumors expressing NTRK, and in 2017, pembrolizumab was approved for tumors with microsatellite instability-high or mismatch repair deficient tumors.
“We are in an exciting era of innovation in cancer treatment as we continue to see development in tissue agnostic therapies, which have the potential to transform cancer treatment,” FDA Acting Commissioner Ned Sharpless, MD, said in a statement. “We’re seeing continued advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.”
Four clinical trials brought promising data for entrictinib and its ability to shrink NTRK fusion-positive tumors. Across the trials, there was an overall response rate (ORR) of 57%, with 7.4% of patients achieving a complete response (CR). There were 31 patients who had tumor shrinkage, 61% of which had responses that lasted 9 months or longer. The most common cancer locations were in the lung, salivary gland, breast, thyroid, and colon/rectum.
The FDA also gave approval to entrectinib for the treatment of adults with metastatic non—small cell lung cancer whose tumors are ROS1 positive. Trials assessing the drug in this setting showed that the entrictinib produced an ORR of 78% of 51 adults with ROS1-postive disease, of which 5.9% experienced a CR. Of the 40 patients who achieved a response, 55% had responses that lasted 12 months or longer.
“Rozlytrek’s FDA approval for two rare types of cancer is an important advance for patients, combining a targeted medicine and genomic testing to bring this new treatment option to patients who are waiting,” Sandra Horning, MD, chief medical officer and head of Global Product Development, Genentech, said in a statement. “Rozlytrek is the first FDA-approved treatment that selectively targets both ROS1 and NTRK fusions, and, importantly, has also shown responses in these rare cancer types that have spread to the brain.”
Common side effects of the treatment include fatigue, constipation, dysgeusia, edema, dizziness, cognitive impairment, weight gain, cough fever, and vision disorders. The most serious side effects include congestive heart failure, central nervous system effects, skeletal fractures, liver damage, and abnormal heart rhythm.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More